The flexibility to keep your trials on track
The COVID-19 pandemic had a substantial impact on the conduct of clinical trials, with many ongoing trials being disrupted and planned trials being delayed. As events unfolded, it became important to look at alternative solutions in many areas to minimise the impact of the pandemic and keep trials on track. The need for a more agile approach to clinical monitoring and associated data review has emerged and this demand is likely to continue into the future.
Our whitepaper examines best practice in clinical monitoring and how to remain agile in challenging conditions.